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Mounting evidence links deregulated protein synthesis to tumorigenesis via the translation initiation factor complex eIF4F.
Components of this complex are often overexpressed in a large number of cancers and promote malignant transformation in
experimental systems. mTOR affects the activity of the eIF4F complex by phosphorylating repressors of the eIF4F complex, the eIF4E
binding proteins. The immunosuppressant rapamycin specifically inhibits mTOR activity and retards cancer growth. Importantly,
mutations in upstream negative regulators of mTOR cause hamartomas, haemangiomas, and cancers that are sensitive to rapamycin
treatment. Such mutations lead to increased eIF4F formation and consequently to enhanced translation initiation and cell growth.
Thus, inhibition of translation initiation through targeting the mTOR-signalling pathway is emerging as a promising therapeutic option.
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Rapamycin (Rapamune
s, Wyeth Ayerst) is a specific inhibitor of
the target of rapamycin (TOR) (for review see Hay and Sonenberg,
2004). The protein kinase TOR genes (TOR1 and TOR2) were first
identified in the early 1990s in a screen for rapamycin-resistant
yeast mutants (Heitman et al, 1991). The mammalian orthologue
(mTOR), is also referred to as FKBP12-rapamycin associated
protein (FRAP), rapamycin and FKBP12 target (RAFT), rapamycin
target (RAPT), or sirolimus effector protein (SEP). Rapamycin
forms a complex with the immunophilin FK506 binding protein-12
(FKBP12), which binds to the FKBP12-rapamycin binding (FRB)
domain of mTOR and inhibits its kinase activity. Rapamycin
inhibits the growth of a broad spectrum of cancers including
rhabdomyosarcoma, neuroblastoma, glioblastoma, small cell lung
carcinoma, osteosarcoma, pancreatic cancer, leukaemia, B-cell
lymphoma, and breast and colon cancer-derived cells (Huang and
Houghton, 2002). The rapamycin analogues, CCI-779 (Wyeth-
Ayerst, PA, USA), RAD001 (Novartis, Switzerland), and AP23573
(Ariad Pharmaceuticals, MA, USA) have shown promise in clinical
trials (Panwalkar et al, 2004).
mTOR functions by integrating extracellular signals (growth
factors and hormones), with amino-acid availability and intra-
cellular energy status to control translation rates and additional
metabolic processes (Hay and Sonenberg, 2004). mTOR enhances
translation initiation in part by phosphorylating two major targets,
the eIF4E binding proteins (4E-BPs) and the ribosomal protein S6
kinases (S6K1 and S6K2) that cooperate to regulate translation
initiation rates.
Translation initiation is implicated in tumorigenesis All nuclear
transcribed eukaryotic mRNAs contain a ‘cap’ structure, m
7GpppN
(where ‘N’ is any nucleotide and ‘m’ is a methyl group), at the 50
terminus. The ‘cap’ is specifically bound by the initiation factor
eIF4E that associates with two additional initiation factors,
eIF4G (a large scaffolding protein) and eIF4A (a helicase which
is believed to unwind mRNA 50 secondary structures), to form the
eIF4F complex, which facilitates the recruitment of ribosomes to
the mRNA (Gingras et al, 1999).
Several studies demonstrated that eIF4E acts as an oncogene (for
a recent review see Mamane et al, 2004). eIF4E levels are limiting
for cap-dependent translation in most systems and overexpression
of eIF4E in rodent cells causes malignant transformation (Lazaris-
Karatzas et al, 1990; Mamane et al, 2004). Therefore, increased
eIF4E expression in cancer cells is thought to enhance eIF4F
complex formation and as a consequence, the translation of a
subset of mRNAs that contain highly structured 50 untranslated
regions (UTRs), such as vascular endothelial growth factor (VEGF)
and ornithine decarboxylase (ODC). Indeed, eIF4E is elevated in
numerous types of cancers, including bronchioalveolar, bladder,
head and neck, liver, colon, and breast cancers (De Benedetti and
Graff, 2004). Consistent with this, two important studies demon-
strated that overexpression of eIF4E in mice promotes lympho-
magenesis (Ruggero et al, 2004; Wendel et al, 2004). Furthermore,
the importance of eIF4E’s role in tumorigenesis is reinforced by
the finding that eIF4F complex is necessary for maintaining
tumour cell growth (Avdulov et al, 2004). Importantly, siRNA
treatment to reduce eIF4E expression inhibits the growth of several
cell lines including those of head and neck squamous carcinoma
cells (Oridate et al, 2005).
Other components of the eIF4F complex are also implicated in
malignant transformation. eIF4GI can transform NIH 3T3 cells,
and is overexpressed in squamous cell lung carcinomas and breast
cancer cell lines (see Mamane et al (2004)). eIF4A is also
overexpressed in human melanoma cell lines and in primary
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findings reinforce a molecular model where increased eIF4F
complex promotes tumorigenesis.
Rapamycin inhibits cap-dependent translation Growth inhibition
by rapamycin is thought to be partially mediated by the inhibition
of cap-dependent translation (Hay and Sonenberg, 2004). The
mammalian 4E-BPs constitute a three-member family of transla-
tional inhibitors that bind to eIF4E, inhibit formation of the eIF4F
complex and thus cap-dependent translation (Gingras et al, 1999).
The 4E-BPs are dephosphorylated as a consequence of rapamycin
treatment. Binding of 4E-BP1 (the best studied 4E-BP family
member) to eIF4E is regulated by its phosphorylation status: the
hypophosphorylated form (residues Thr37 and 46) of 4E-BP1
binds very tightly to eIF4E and inhibits cap-dependent translation.
In response to stimuli such as growth factors, hormones, nutrients,
or increased energy levels, mTOR phosphorylates 4E-BP1 primarily
at residues Ser65 and Thr73. As a result, eIF4E is released from 4E-
BP1 with a subsequent increase in cap-dependent translation
(Mamane et al, 2004).
Several studies addressed the role of the 4E-BPs in tumour
suppression. For example, 4E-BP overexpression counteracts
eIF4E-, src-, or ras-mediated cellular transformation (Mamane
et al, 2004). Also, a nonphosphorylatable mutant of 4E-BP1, which
constitutively binds eIF4E, inhibits breast cancer cell growth more
strongly than wild-type 4E-BP1 (Avdulov et al, 2004). In addition,
the 4E-BPs appear to mediate rapamycin-sensitivity since rhabdo-
myosarcoma cells expressing very low levels of 4E-BP1 are
refractory to growth inhibition by rapamycin (Dilling et al,
2002). Thus, the 4E-BPs are considered to be important mTOR
targets that modulate cancer cell growth through a mechanism that
involves cap-dependent translation.
Ribosomal protein S6 kinase The ribosomal protein S6 kinases
are also important substrates of mTOR. S6K1 (p70S6K; the better
characterised S6 kinase) is implicated in the positive regulation
of cell growth and proliferation (Fumagalli and Thomas, 2000).
Interestingly, S6K1 activation correlates with enhanced translation
of a subset of mRNAs that contain a terminal 50 oligopyrimidine
tract (TOP mRNAs) (Fumagalli and Thomas, 2000). These mRNAs
encode ribosomal proteins, elongation factors, the poly-A binding
protein and other components of the translational machinery
that become selectively translated in response to growth factors.
However, TOP mRNA translation remains intact even when both
S6K1 and S6K2 genes are genetically disrupted in mice (Pende
et al, 2004), indicating that S6Ks are not essential for the regulation
of TOP mRNA translation.
S6K regulates mTOR through a negative feedback signalling
pathway that affects insulin receptor substrate-1 (IRS-1) (Figure 1).
S6K was shown to directly phosphorylate IRS-1 to inhibit
phospohatidylinositol-3-kinase (PI3K) and Akt activation
(Harrington et al, 2004). S6K activation decreases IRS-1 expres-
sion, while rapamycin treatment restores IRS-1 expression
(Harrington et al, 2004). Also, deletion of S6K1 in mice renders
them resistant to age- and high-fat diet-induced obesity while
enhancing insulin sensitivity (Um et al, 2004). Lastly, Akt
activation in response to insulin is enhanced in S6K-null mice,
thus implicating S6K1 in diabetes and obesity (Um et al, 2004).
Other translational targets of mTOR Other rapamycin-sensitive
targets involved in translational regulation exist. The translation
initiation factor eIF4B, which stimulates the activity of eIF4A in
unwinding duplex RNA, is phosphorylated by S6K1 on serine 422
(Raught et al, 2004). mTOR also mediates the phosphorylation of
serines 1108, 1148, and 1192 in the C-terminus of eIF4G (Raught
et al, 2000). In addition, mTOR regulates the elongation stage of
protein synthesis by modulating elongation factor (eEF2) kinase
(Proud, 2004).
PI3K/Akt/mTOR signaling Growth factors, mitogens and hor-
mones activate the PI3K signaling pathway and consequently
mTOR (Hay and Sonenberg, 2004) (Figure 1). Nutrients (amino
acids, glucose) also regulate mTOR activity to affect translation
(Proud, 2004). PI3K phosphorylates phosphatidylinositol-4,5-bi-
sphosphate (PIP2) to generate phosphatidylinositol-3,4,5-tri-
phosphate (PIP3). PIP3 binds and activates pleckstrin homology
(PH) domain-bearing proteins such as Akt and the phosphoinosi-
tide dependent kinase (PDK) family members. PDK1 and the Ser/
Thr kinase Akt are recruited to the membrane where PDK1
phosphorylates and activates Akt. In turn, Akt phosphorylates the
tuberous sclerosis complex, TSC1/TSC2 (hamartin/tuberin) that
serves as a GTPase activating protein (GAP) for the small G
protein, Ras homolog enriched in brain (Rheb). Rheb, in its GTP-
bound state, can activate mTOR.
Negative regulators of mTOR are implicated in tumour
suppression
PTEN PTEN is a lipid phosphatase that acts on the lipid substrate
PIP3 to convert it to PIP2. PIP3 accumulation results from PTEN-












































Figure 1 mTOR signaling to translation initiation. mTOR signaling
regulates translation initiation by integrating several different inputs. Insulin,
hormones and growth factors activate the PI3K/Akt signaling cascade. Akt
receives inputs from PDK1 and the rictor/GbL/mTOR complex. Energy
status (the AMP/ATP ratio) modulates AMPK activity. These pathways
affect TSC1/2 to regulate mTOR activity via Rheb. The raptor/GbL/mTOR
complex mediates the phosphorylation of 4E-BP and S6K. Pharmacological
inhibition of PI3K (wortmannin or LY294002) and mTOR (rapamycin or its
analogs), or activation of AMPK (by increased AMP/ATP, metformin or
AICAR) are indicated.
mTOR signaling: implications for cancer and anticancer therapy
E Petroulakis et al
196
British Journal of Cancer (2006) 94(2), 195–199 & 2006 Cancer Research UKangiogenesis (Inoki et al, 2005a). PTEN is frequently mutated in
many cancers and in a group of cancer-like syndromes including
Cowden, Lhermitte–Duclos, Bannayan–Zonana, and Proteus
syndromes that are characterised by the emergence of hamartomas
(Inoki et al, 2005a). A critical outcome of PTEN inactivation is an
increase in mTOR activity, resulting in the phosphorylation of 4E-
BPs and S6Ks. Strikingly, PTEN /  cells are hypersensitive to
growth inhibition by rapamycin and CCI-779 (Guertin and
Sabatini, 2005).
AMP-activated protein kinase (AMPK) mTOR activity becomes
repressed under conditions of energy deprivation, in which an
elevated AMP/ATP intracellular ratio causes activation of AMPK.
Stressful conditions, such as nutrient deprivation, hypoxia, heat
shock, and ischaemia diminish cellular energy reserves. The link
between mTOR inhibition and AMPK was first demonstrated with
the use of AICAR (50-phosphoribosyl-5-aminoimidazole-4-carbox-
amide ribonucleoside), an AMPK activator, thus linking the amino
acid- and energy-sensing functions of mTOR. Metformin, an
antidiabetic drug, also activates AMPK and is hypothesised to
reduce the risk of cancer in patients with type 2 diabetes (Evans
et al, 2005). Thus, targeting AMPK may be an interesting
therapeutic option for cancer therapy.
LKB1 LKB1 is a serine/threonine kinase that phosphorylates and
activates AMPK. LKB1 is frequently mutated in Peutz-Jeghers
syndrome (PJS), an autosomal dominant inherited cancer predis-
posing patients to the development of tumours mainly throughout
the gastrointestinal tract. Disruption of LKB1 in mice causes
gastrointestinal and hepatic polyps (Bardeesy et al, 2002). In
LKB1-deficient cells, phosphorylation AMPK is defective and cells
resist mTOR inactivation in response to AICAR (Shaw et al, 2004).
Importantly, 4E-BP1 is less enriched in eIF4E-bound cap analogue
precipitates from LKB1-deficient cells (Shaw et al, 2004). This is
indicative of enhanced eIF4F formation as a result of increased
mTOR signaling caused by LKB1-deficiency. LKB1-mediated
inhibition of mTOR also involves the TSC1/2 complex, thus
demonstrating the link between LKB1 and mTOR through the
regulation of AMPK and TSC1/2 activities (Shaw et al, 2004).
TSC1/TSC2 TSC1 and TSC2 are mutated in tuberous sclerosis
complex (TSC) patients. In response to low energy levels, TSC2
becomes phosphorylated by AMPK, resulting in increased stability
of the TSC1/2 complex. The stabilised TSC1/2 complex inhibits
mTOR and protects cells from energy deprivation-induced
apoptosis (see recent reviews by (Inoki et al, 2005b; Kwiatkowski
and Manning, 2005)). TSC2 is also phosphorylated by Akt leading
to its inactivation and consequently to increased mTOR activity.
Furthermore, S6K phosphorylation is elevated in TSC /  cells
and is rapidly abrogated by rapamycin treatment. Activation of the
extracellular signal-regulated kinase (Erk) by the Ras signaling
pathway also leads to TSC1/2 inactivation through phosphoryla-
tion of TSC2 on Ser664 (Ma et al, 2005). Taken together, the
TSC1/2 complex functions as a key player in the regulation of the
mTOR pathway by receiving inputs from PI3K/PTEN/Akt and Ras
signalling pathways, energy levels, and amino acids to regulate
translation initiation and affect cell growth and proliferation.
mTOR COMPLEXES REGULATE RAPAMYCIN
SENSITIVITY
Recent findings shed new light on the mechanisms of mTOR
sensitivity to rapamycin. Three key interacting partners of mTOR
(raptor, GbL, and rictor) modulate many of mTOR’s rapamycin-
sensitive and insensitive functions. These evolutionarily conserved
proteins have been characterised in yeast and mammalian cells.
Raptor is the mammalian ortholog of yeast Kog1 (Kontroller of
growth 1) (reviewed in Kim and Sabatini (2004), Lorberg and Hall
(2004)). Raptor interacts with mTOR and tethers it to its
downstream effectors through a TOS (TOR signaling) motif found
in the mTOR substrates, 4E-BP1 and S6K1 (amino acid sequences:
FEMDI and FDIDL, respectively) (reviewed in Proud (2004)). The
raptor/mTOR interaction is nutrient-sensitive and is dependent on
the presence of another partner, GbL (a mammalian ortholog of
yeast Lst8p) (Guertin and Sabatini, 2005). GbL/mLst8 interacts
with the mTOR kinase domain independently of raptor and
potentiates mTOR activity. Rictor (rapamycin insensitive compo-
nent of TOR; the yeast AVO3 ortholog), is involved in the control
of cytoskeleton organisation (Lorberg and Hall, 2004; Guertin and
Sabatini, 2005). Unlike raptor/GbL/mTOR (mTORC1 complex),
the rictor/mTOR (mTORC2 complex) interaction is insensitive to
rapamycin treatment. Most importantly, the rictor/mTOR complex
is required for Akt phosphorylation on Ser473 to achieve its
full activation (Guertin and Sabatini, 2005). Although the activity
of the rictor/mTOR complex is insensitive to short periods
of rapamycin treatment, it has been suggested that long-term
exposure to rapamycin could prevent newly-synthesised mTOR
molecules from associating with rictor, thereby preventing rictor/
mTOR-mediated Akt phosphorylation (Guertin and Sabatini,
2005). This model predicts that rictor could serve as a new
therapeutic target in mTOR-linked hamartoma syndromes (such
as tuberous sclerosis) and PTEN-mutated cancers, where rapa-
mycin therapy has already proven beneficial.
RAPAMYCIN IN COMBINATION THERAPY
In Peutz Jeghers syndrome, Tuberous Sclerosis, and other diseases
where PTEN is inactivated, the use of rapamycin as a clinical
means to reverse the effect of elevated mTOR activity is an
attractive option (Inoki et al, 2005a). These diseases are distinct
from other hamartoma-associated disorders (such as VHL
syndrome) since they have an established molecular link to mTOR
(Inoki et al, 2005a). Earlier studies demonstrated that PTEN-
inactivated tumour cells exhibit enhanced sensitivity to the
rapamycin analog CCI-779 (Guertin and Sabatini, 2005). More
recently, several studies have shown that rapamycin treatment,
in combination with other chemotherapeutic drugs, can lead to
enhanced selective killing of cancer cells. In particular, the protein
tyrosine kinase (PTK) inhibitor, Imatinib (Gleevec, STI571)
synergises with rapamycin to inhibit BCR/ABL transformed cells
(Mohi et al, 2004). The effect of rapamycin may be enhanced as a
result of Imatinib-induced Akt/mTOR signaling, a complication
that is thought to lead to Imatinib resistance (Burchert et al, 2005).
Rapamycin can also synergise with paclitaxel, carboplatin, and
vinorelbine to induce apoptosis in breast cancer cells (Mondesire
et al, 2004). Cisplatin-induced apoptosis of A549 lung cancer cells
is also significantly enhanced when combined with RAD001
(Beuvink et al, 2005). This could be in part due to reduced
translation of p53-activated p21 mRNA in A549 and MCF7 cells
treated with RAD001, thereby allowing the dosage of cisplatin to be
reduced (Beuvink et al, 2005). Also, the use of the EGFR/VEGFR
inhibitor, AEE788, in combination with RAD001 greatly decreased
tumour growth in glioma xenografts (Goudar et al, 2005).
Furthermore, targeting the glycolytic pathway in combination
with mTOR inhibition may also be useful in cases where DNA-
damaging agents are less efficient in inhibiting growth and
promoting apoptosis of cancer cells (Xu et al, 2005).
TARGETING THE TRANSLATIONAL APPARATUS AS
A THERAPEUTIC APPROACH
A critical outcome of mTOR activation is the phosphorylation of
several components of the translational apparatus, which mediate
translation initiation and cell proliferation. A major rate-limiting
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at the 50 mRNA cap structure. Rapamycin inhibits eIF4F formation
largely in part through 4E-BP dephosphorylation. Several studies
have implicated the eIF4E/4E-BP pathway as a putative down-
stream target of mTOR in tumorigenesis (Avdulov et al, 2004;
Ruggero et al, 2004; Wendel et al, 2004). Inhibition of mTOR-
mediated cap-dependent translation, through the use of rapamycin
is insufficient to elicit a complete inhibition of cancer cell
proliferation. This may be in part due to chemoresistance that
arises as a consequence of Akt-mediated activation. Hence, the
benefits of rapamycin treatment may not be realised in all cases
of aberrant mTOR activity. Since experimental models implicate
translation initiation directly in cancer cell growth, it would be of
interest to develop molecules that specifically target downstream
components of the mTOR signaling pathways, which control eIF4F
formation.
Recent work has implicated microRNAs (miRNAs) in the
regulation of translation initiation by inhibiting cap-dependent
translation (Pillai et al, 2005). Importantly, many miRNAs
function as oncogenes or tumour suppressors (Chen, 2005).
Thus, it is possible that the mTOR pathway could control the
activity of miRNAs in cancer. It will be important to continue
to study the PI3K/Akt/mTOR pathway and its downstream
effectors of translation as molecular targets for anticancer
therapies.
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